List of Eskata drug patents

Eskata is owned by Aclaris.

Eskata contains Hydrogen Peroxide.

Eskata has a total of 6 drug patents out of which 1 drug patent has expired.

Expired drug patents of Eskata are:

  • US7381427

Eskata was authorised for market use on 14 December, 2017.

Eskata is available in solution;topical dosage forms.

Eskata can be used as treatment of seborrheic keratoses that are raised.

The generics of Eskata are possible to be released after 04 July, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7381427 ACLARIS Seborrheic keratosis treatment
Jun, 2022

(8 months ago)

US10098910 ACLARIS Peroxide formulations and methods and applicators for using the same
Apr, 2035

(12 years from now)

US9980983 ACLARIS Peroxide formulations and methods and applicators for using the same
Apr, 2035

(12 years from now)

US10493103 ACLARIS Peroxide formulations and methods and applicators for using the same
Apr, 2035

(12 years from now)

US10729720 ACLARIS Peroxide formulations and methods and applicators for using the same
Apr, 2035

(12 years from now)

US9675639 ACLARIS Peroxide formulations and methods and applicators for using the same
Jul, 2035

(12 years from now)

Drugs and Companies using HYDROGEN PEROXIDE ingredient

Market Authorisation Date: 14 December, 2017

Treatment: Treatment of seborrheic keratoses that are raised

Dosage: SOLUTION;TOPICAL

More Information on Dosage

ESKATA family patents

14

United States

3

Australia

2

China

2

Brazil

2

Canada

2

Singapore

2

Mexico

2

Japan

2

European Union

1

Austria

1

Korea, Republic of

1

Denmark

1

Russia

1

Spain

1

Germany

1

Israel

1

New Zealand

1

Portugal

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic